
#### How to use WHO's family planning guidelines and tools

#### Mary Eluned Gaffield Promoting Family Planning Team Department of Reproductive Health and Research

Training Course in Sexual and Reproductive Health Research Geneva 2011








#### Learning objectives

- To understand the purpose of WHO's family guidelines and tools.
- To be able to identify and apply medical eligibility criteria and practice recommendations for family planning service delivery.
- To know how to use family planning tools for service provision.





The need for evidence-based guidance


• To base family planning practices on the best available published evidence

 To address misconceptions regarding who can safely use contraception

To reduce medical barriers

 To improve access and quality of care in family planning






## WHO guidelines and tools








#### Guidance developed through consensus

#### Expert Working Group meetings:

- Country experts
- Representatives of:
  - UNFPA
  - World Bank
  - IPPF
  - USAID
  - CDC
  - NICHD
  - Engender Health

- FHI
- JHU/CCP
- JHPIEGO
- Intra-Health
- Georgetown University Medical Center
- Management Sciences for Health







# Medical eligibility criteria for contraceptive use (MEC)




Fourth edition, 2009

COS Barrer methods IUDs Farmin measures head relations Locations measures frequencies and the entrateries interaction designed CO cellular interactions designed to have surgical strengthen LOCE Facility measures barrel methods IUDs neurity measures barrel methods IUDs neurity measures barrel methods Locationed termination formations designed termination formations and the second termination formation control in the measures control methods IUDs neurity measures and methods IUDs neurity measures and methods IUDs neurity measures and the second IUDs of the measures of the second IUDs of the measures control methods IUDs (CON



## Purpose: Who can safely use contraceptive methods?

- First published in 1996, revised through expert meetings held in 2000, 2003, and 2008
- Fourth edition offers ≈ 1800 recommendations for 19 methods
- Available in English, French, Spanish, Arabic, Chinese, Turkish, Romanian, Portuguese, Laotian, Vietnamese, Mongolian








#### **Classification of recommendations**

- **Divided** into four categories:
  - 1 = a condition for which there is no restriction for the use of the contraceptive method,
  - 2 = a condition where the advantages of using the method generally outweigh the theoretical or proven risks,
  - 3 = a condition where the theoretical or proven risks usually outweigh the advantages of using the method,
  - 4 = a condition which represents an unacceptable health risk if the contraceptive method is used.






#### **Classification of recommendations - continued**

- Four categories can be simplified where resources for clinical judgement are limited:
  - Woman is medically eligible to use the method (categories 1 & 2)
  - Woman is not medically eligible to use the method (categories 3 & 4)
- Initiation and continuation
  - Where warranted, recommendations will differ if a woman is starting a method (I = initiation) or continuing a method (C = continuation)
    - Example: women with current PID are a category '4' for initiating a copper IUD, but a category '2' for if they are continuing to use an IUD.
  - Unless noted, recommendations are the same for initiation and continuation of a method








# Classification of recommendations - female and male surgical sterilization

- **Divided** into four categories:
  - Accept 'A' = There is no medical reason to deny sterilization to a person with this condition,
  - Caution 'C' = The procedure is normally conduced in a routine setting, but with extra preparation and precautions,
  - Delay 'D' = The procedure is delayed until the condition is evaluated and or corrected. Alternative temporary methods of contraception should be provided,
  - Special 'S' = The procedure should be undertaken in a setting with an experienced surgeon and staff, equipment needed to provide general anaesthesia, and other back-up medical support. The capacity to decide the most appropriate procedure and anaesthesia regimen is needed. Alternative temporary methods of contraception should be provided, if referral is required or there is otherwise any delay.






| CONDITION  | COC          | CIC         | P/R         | POP          | dmpa<br>Net-en | LNG/<br>ETG<br>Implants | Cu-IUD | LNG-IUD |
|--|--------------|-------------|-------------|--------------|----------------|-------------------------|--------|---------|
| l = Ini  | tiation, C = | Continuatio | on, BF = Br | reastfeeding | I, NA = not    | applicable              |        |         |
| BREAST DISEASE   |              |             |             |              |                |                         |        |         |
| a) Undiagnosed mass  | 2*           | 2*          | 2*          | 2*           | 2*             | 2*                      | 1      | 2       |
| b) Benign breast disease                                       | 1            | 1           | 1           | 1            | 1              | 1                       | 1      | 1       |
| c) Family history of cancer                                    | 1            | 1           | 1           | 1            | 1              | 1                       | 1      | 1       |
| d) Breast cancer   |              |             |             |              |                |                         |        |         |
| (i) current  | 4            | 4           | 4           | 4            | 4              | 4                       | 1      | 4       |
| (ii) past and no evidence<br>of current disease for 5<br>years | 3            | 3           | 3           | 3            | 3              | 3                       | 1      | 3       |
| ENDOMETRIAL CANCER   |              |             |             |              |                |                         | I C    | I C     |
|  | 1            | 1           | 1           | 1            | 1              | 1                       | 4 2    | 4 2     |
| OVARIAN CANCER   |              |             |             | 10           |                | 8                       | I C    | I C     |
|  | 1            | 1           | 1           | 1            | 1              | 1                       | 3 2    | 3 2     |
| UTERINE FIBROIDS   |              | e           |             |              |                | i                       |        |         |
| a) Without distortion of the<br>uterine cavity                 | 1            | 1           | 1           | 1            | 1              | 1                       | 1      | 1       |
| b) With distortion of the uterine cavity                       | 1            | 1           | 1           | 1            | 1              | 1                       | 4      | 4       |

Source: Medical Eligibility Criteria for Contraceptive Use. WHO: Geneva, 2009.







#### SUMMARY TABLES

| CONDITION               | COC            | CIC        | P/R         | POP        | DMPA<br>Net-en | LNG/<br>ETG<br>Implants | Cu-IUD | LNG-IUD |
|-------------------------|----------------|------------|-------------|------------|----------------|-------------------------|--------|---------|
| . [=]                   | nitiation, C = | Continuati | on, BF = Br | eastfeedin | g, NA = not    | applicable              |        |         |
| PERSONAL CHARACTERIST   | ICS AND REP    | RODUCTIVE  | HISTORY     |            |                |                         |        |         |
| SMOKING                 | 20 D           |            |             |            |                | _                       |        |         |
| a) Age < 35             | 2              | 2          | 2           | 1          | 1              | 1                       | 1      | 1       |
| b) Age ≥ 35             |                |            |             |            |                |                         |        |         |
| (i) <15 cigarettes/day  | 3<br>4         | 2          | 3           | 1          | 1              | 1                       | 1      | 1       |
| (ii) >15 cigarettes/day | 4              | 3          | 4           | 1          | 1              | 1                       | 1      | 1       |

(Source: Medical Eligibility Criteria for Contraceptive Use. WHO, Geneva, 2009)






#### Case study: which methods are safe ?

- A 24 year old woman with a family history of breast cancer ?
  - COC ?
  - IUD ?
  - Injectable ?
  - Implants ?

- A 38 year old woman who smokes less than 1/2 pack of cigarettes per day ?
  - COC ?
  - IUD ?
  - Implants ?
  - Injectable ?





## **MEC Wheel**



- Offers accessible MEC guidance for most commonly encountered medical conditions.
- Conditions that are either '1' or '2' on back of wheel.
- Locate condition of interest, then turn wheel to identify eligibility category.
- Available in many languages: English, French, Spanish, Chinese, Arabic, Mongolian, Azeri, Latvian, Lithuanian, Russian, Sri Lankan, Myanmar, Armenian, Nepali, Indonesian, Turkish, Burmese, Ukrainian, Khmer


#### **Electronic wheel demonstration**

 Electronic wheel allows you to consult common conditions easily

Now, please click this link to open the electronic wheel: http://www.who.int/reproductivehealth/publications/f amily\_planning/wheel\_v4\_2010\_EN.swf

Note: The electronic wheel was attached in this presentation with audio.






## Selected practice recommendations for contraceptive use



Purpose: How to safely deliver contraceptive methods?

- First published in 2000, revised through expert meetings held in 2004 and 2008
  - Second edition offers 33 practice recommendations

Available in English, French, Spanish, Arabic, Chinese, Romanian, Portuguese, Russian, Vietnamese, Sri Lankan








#### **Practice questions**

#### Examples:

- when to start
- when to re-administer
- how to manage problems
  - missed pills
  - bleeding (progestogen-only methods and IUDs)
  - prophylactic antibiotics and IUD insertion
- what examinations and tests are required before starting a method







#### 1. When can a woman start combined oral contraceptives (COCs)?

Note: The woman may be provided with COCs in advance with appropriate instructions on pill initiation, provided she is medically eligible.

#### Having menstrual cycles

- She can start COCs within 5 days after the start of her menstrual bleeding. No additional contraceptive protection is needed.
- She also can start COCs at any other time, if it is reasonably certain that she is not pregnant. If it has been more than 5 days since menstrual bleeding started, she will need to abstain from sex or use additional contraceptive protection for the next 7 days.

#### Amenorrhoeic


 She can start COCs at any time, if it is reasonably certain that she is not pregnant. She will need to abstain from sex or use additional contraceptive protection for the next 7 days.

#### Postpartum (breastfeeding)\*

- If she is more than 6 months postpartum and amenorrhoeic, she can start COCs as advised for other amenorrhoeic women.
- If she is more than 6 months postpartum and her menstrual cycles have returned, she can start COCs as advised for other women having menstrual cycles.
- \* Additional guidance from the Medical eligibility criteria for contraceptive use. Third edition, 2004. Women less than 6 weeks postpartum who are primarily breastfeeding should not use COCs. For women who are more than 6 weeks but less than 6 months postpartum and are primarily breastfeeding, use of COCs is not usually recommended unless other more appropriate methods are not available or not acceptable.

#### Postpartum (non-breastfeeding)\*

 If her menstrual cycles have not returned and she is 21 or more days postpartum, she can start COCs immediately, if it is reasonably certain that she is not pregnant. She will need to abstain from sex or use additional contraceptive protection for the next 7 days.







#### Routine exams or tests

| Exam or screening      | Hormonal methods | IUD | Condoms /<br>Spermicide s |   |
|------------------------|------------------|-----|---------------------------|---|
| Breast exam            | С                | С   | С                         | С |
| Pelvic exam            | С                | А   | С                         | А |
| Cervical cancer        | С                | С   | С                         | С |
| Routine lab tests      | С                | С   | С                         | С |
| Hemoglobin             | С                | В   | С                         | В |
| STI risk<br>assessment | С                | А   | С                         | С |
| STI screening          | С                | В   | С                         | С |
| Blood pressure         | **               | С   | С                         | Α |

Class A: essential and mandatory in all circumstances Class B: contributes substantially to safe and effective use Class C: does not contribute substantially to safe and effective use


> Department of Reproductive Health and Research



### Decision-making tool for family planning clients and providers




- A tool for providers and their clients. Contains evidence-based technical information
- Contains evidence-based technical information and a counseling process
- To be used with clients in the clinic
- Uses simple language
- Illustrations for clients










# Improved counseling has the potential to :

Increase:

- Client satisfaction
- Provider satisfaction
- Correct use of methods
- Continuation of use


Reduce:

- Dropout from services
- Unnecessary health risks
- Method failure
- Unwanted pregnancy
















#### A structured counselling process



#### Main points on a CLIENT PAGE




Decision-making question: client needs to respond and participate before going to next page

Department of

Reproductive Health and Research



#### Main points on a PROVIDER PAGE



Department of

Reproductive Health and Research



#### **Counseling** Icons








Ask if client has questions

Offer support

Check understanding

Listen carefully






hrp

-

## **Choosing a method**



## **Choosing a method:**

## Do you have a method in mind?



#### If you do, let's talk about how well it suits your needs

- · What have you heard about it?
- What do you like about it?


If not, we can find a method right for you

#### Important for choosing a method: Do you need protection from pregnancy AND sexually transmitted infections?

- Focus on what she knows about the method
- 2. Check understanding of the method
- 3. Can also discuss other options








## **Best practices in FP counseling:**

## You can find a method right for you




#### No method in mind? We can discuss:

- Your experiences with family planning
- What you have heard about family planning methods
- Your plans for having children
- Protection from sexually transmitted infections (STIs) or HIV/AIDS
- Your partner's or family's attitudes
- Other needs and concerns



## 1. Focus on needs and situation


#### **Comparing methods**



#### 2. Compare methods in light of needs and situation




## **Dual Protection**



#### Dual Protection = Protection from pregnancy and STIs/HIV








### **Dual Protection**

#### Do you have a method in mind?




# Part of the decision-making process

#### Copper IUD

- Small device that fits inside the wornb
- Very effective
- Keeps working up to 10 years, depending on type
- We can remove it for you whenever you want
- Very safe
- Might increase menstrual bleeding or cramps
- No protection against STIs or HIV/AIDS

Do you want to know more about the IUD, or talk about a different method?


## **Special Needs**




Reproductive Health and Research




## **Returning Clients**








## **Returning Clients**




#### Find the right page in the section (no tabs) SHR Department of Reproductive Health and Research

hrp






## **Managing problems**











#### **Method Sections**










go to next page.


another method, but not monthly injectable.

P2


# **Appendices: extra counseling tools**












## 8: Facts about STIs and HIV/AIDS


|           | Bpermioldes | 3 Minatia a requally transmitted   | rearrance control to the set   | Teating, counselling, and treatment for  |  |
|-----------|-------------|--|--|--|--|
| affective |             | Infection (STI)?   | Mistare HM and AIDS?   | HWAIDS   |  |
|           |             | <ul> <li>An STIIs an Intection halican be spread<br/>from person to person by sexual contact.</li> <li>Some STB cambe tharmellied by any<br/>sexual act halinuolues contact be twen<br/>the perids, usgine, anus and/or mouth.<br/>For best protection, a couple chould<br/>use condoms, or avoid any contact in<br/>the geni bit area (including oral and<br/>analise).</li> <li>Bit smay or may no toou re-<br/>gymp time. Some cause pain. Often,<br/>however, people (carticularly women)<br/>may not know that hey have an STI unit<br/>a mater problem develops.</li> <li>Bome common 8 th coan be theated<br/>and oursel with antibiolics. These STE<br/>include gonomoles, chiamydial intection,<br/>chanced and sybilis. These STE<br/>include gonomoles, chiamydial intection,<br/>chanced and sybilis. These STE<br/>include gonomoles, thermydial intection,<br/>chanced and sybilis. These main<br/>papilloma unus (HPV) and HIV (see<br/>right).</li> <li>Ma woman has an STI, she is alignater<br/>disk for some reproductue cancers, petide<br/>inducate and HIV intection. Bome<br/>Bit cau as use intertift y and de ah,<br/>papilloma due si herbit the and de ah,<br/>partioularly in the tested d.<br/>To see which is a risk for S TB, see<br/>Deal Promotion et al. page DPC</li> </ul> | example, preumoria, luberculosis, mataria,<br>shingles or diamboea).<br>• After a person contracts HIV, digins and<br>symptomic of dokne schormally take many<br>years to develop. | <ul> <li>A percentilions (Sfb HIV usually looks and field healthy, Host people with HIV do not know that hey are carrying the utrus.</li> <li>To preuent intections and to promote access to care and treatment, it is important for a percente know higher HIV of buts.</li> <li>The only way to bill the person has HIV is a blood lest. Blood lest can usually de tect HIV 6 weeks after the person has been exposed to the utrus. Positive lest insult need continuation before diagnosing or courselling the patient.</li> <li>Recommend HIV lesting for all clients who way be at risk of acculting the client. And the second content of the second content of the second lest is the second content of the second conten</li></ul> |  |
|           |             | Anyone at n  | Anyone at risk for STIs, including HIV, should use CONDOMS!  |  |  |



# Reproductive Choices and Family Planning for People with HIV




- Two-day training and job aid an adaptation of the Decision-Making Tool for Family Planning Clients and Providers
  - Developed as part of Integrated Management of Adolescent and Adult Illness (IMAI) series
- Field tested in Uganda and Lesotho
- Developed in collaboration with the INFO Project at Johns Hopkins Bloomberg School of Public Health
- First edition published in 2006 and available on WHO website






# Road map of this counseling tool




# Safer sex and living with HIV

- Can still enjoy sexual intimacy
- There are ways to lower risk
- Some sexual activities are safer than others







# Do you know your partner's HIV status?

## **Questions about sexual relationships:**

- Does client know the HIV status of sex partner(s)?
- Does partner(s) know client's HIV status?

## If a partner's status is unknown:

- Discuss reasons that client's partner(s) should be tested for HIV.
  - Even if you are HIV positive, your partner may not be infected.
  - When both partners know their status, they can then know how best to protect themselves.
- When status is unknown, assume your partner is negative and needs protection from infection. Important to use condoms.

## If a partner is HIV negative:

- Explain that it is common for a person who is HIV positive to have a partner who is HIV negative.
- HIV is not transmitted at every exposure, but HIV-negative partners are at a high risk of infection.
- Important to always use condoms or avoid penetrative sex.

## If both you and your partner are HIV positive:

- If mutually faithful, the couple may choose not to use condoms and may choose another method for pregnancy protection.
- If not mutually faithful or faithfulness is uncertain, condoms should be used or penetrative sex avoided to prevent STIs.

## How to use this page:

• Discuss HIV status of client and partner(s) so they can know how to best protect themselves.

For all

clients


- If client has not disclosed HIV status to partner, discuss benefits and risks of disclosure.
- Help client develop strategy for disclosure, if client is ready.
- Strongly encourage and help with partner testing and counselling.

*Next step:* Discuss safer sex and living with HIV (go to next page).


## Preparing to disclose HIV status

- Who to tell?
- When to tell?
- How to tell? Make a plan.
- What you will say? Practice with client.
- What will you say or do if ...?
- If there is a risk of violence, discuss whether or not to disclose, or how to disclose with counsellor or friend present.

# Family Planning: A Global Handbook for Providers



- Reference guide for family planning providers & summarizes WHO family planning guidance
- Launched in October 2007, updated in 2011
- Over 100,000 copies distributed
- Published by the INFO Project at the Johns Hopkins Bloomberg School of Public Health. Endorsed by nearly 50 organizations






# **Contents: Method chapters**

- Combined oral contraceptives (COCs)
  - Patch
  - Vaginal Ring
- Combined injectable contraceptives (CICs)
- Emergency contraceptive pills
- Progestogen-only pills
- Progestogen-only injectables
- Implants
- Copper-bearing IUD
  - LNG-IUD

- Vasectomy
- Female sterilization
- Lactational amenorrhea method
- Fertility awareness-based methods
  - Withdrawal
- Condom
- Female condom
- Spermicides/diaphragm






# **Chapter Headings**

- Key points
- Helping the Client Decide about Combined Oral Contraceptives (COCs)
- Side effects, health benefits, and risks
   COCs and cancer
- Who can and cannot use combined oral contraceptives
  - Medical eligibility criteria
- Providing combined oral contraceptives
- Following up users of combined oral contraceptives
- Questions and Answers







#### CHAPTER 4

# Progestin-Only Injectables


#### **Key Points for Providers and Clients**

- Bleeding changes are common but not harmful. Typically, irregular bleeding for the first several months and then no monthly bleeding.
- Return for injections regularly. Coming back every 3 months (13 weeks) for DMPA or every 2 months for NET-EN is important for greatest effectiveness.
- Injection can be as much as 2 weeks early or late. Client should come back even if later.
- Gradual weight gain is common.
- Return of fertility is often delayed. It takes several months longer on average to become pregnant after stopping progestinonly injectables than after other methods.

#### What Are Progestin-Only Injectables?

- The injectable contraceptives depot medroxyprogesterone acetate (DMPA) and norethisterone enanthate (NET-EN) each contain a progestin like the natural hormone progesterone in a woman's body. (In contrast, monthly injectables contain both estrogen and progestin. See Monthly Injectables, p. 81.)
- Do not contain estrogen, and so can be used throughout breastfeeding and by women who cannot use methods with estrogen.
- DMPA, the most widely used progestin-only injectable, is also known as "the shot," "the jab," the injection, Depo, Depo-Provera, Megestron, and Petogen.
- NET-EN is also known as norethindrone enanthate, Noristerat, and Syngestal. (See Comparing Injectables, p. 359, for differences between DMPA and NET-EN.)

Progestin-Only Injectables 59









- Given by injection into the muscle (intramuscular injection). The hormone is then released slowly into the bloodstream. A different formulation of DMPA can be injected just under the skin (subcutaneous injection). See New Formulation of DMPA, p. 63.
- Work primarily by preventing the release of eggs from the ovaries (ovulation).

#### How Effective?

More effective

Less

effective

Effectiveness depends on getting injections regularly: Risk of pregnancy is greatest when a woman misses an injection.

- As commonly used, about 3 pregnancies per 100 women using progestin-only injectables over the first year. This means that 97 of every 100 women using injectables will not become pregnant.
- When women have injections on time, less than 1 pregnancy per 100 women using progestin-only injectables over the first year (3 per 1,000 women).

Return of fertility after injections are stopped: An average of about 4 months longer for DMPA and 1 month longer for NET-EN than with most other methods (see Question 7, p. 79).

Protection against sexually transmitted infections (STIs): None

### ion). The - Irregular bleeding

 NET-EN affects bleeding patterns less than DMPA. NET-EN users have fewer days of bleeding in the first 6 months and are less likely to have no monthly bleeding after one year than DMPA users.

Side Effects, Health Benefits, and Health Risks

Side Effects (see Managing Any Problems, p. 75)

Changes in bleeding patterns including, with DMPA:

Some users report the following:

First 3 months:

Irregular bleeding
 Prolonged bleeding
 At one year:
 No monthly bleeding
 Infrequent bleeding

- Weight gain (see Question 4, p. 78)
- Headaches
- Dizziness
- Abdominal bloating and discomfort
- Mood changes
- Less sex drive

Other possible physical changes:


Loss of bone density (see Question 10, p. 80)

#### Why Some Women Say They Like Progestin-Only Injectables

- Do not require daily action
- Do not interfere with sex
- Are private: No one else can tell that a woman is using contraception
- Cause no monthly bleeding (for many women)
- May help women to gain weight









# Progestin-Only Injectables

#### Known Health Benefits

#### DMPA

Helps protect against:

- Risks of pregnancy
- Cancer of the lining of the uterus (endometrial cancer)
- Uterine fibroids

May help protect against:

- Symptomatic pelvic inflammatory disease
- Iron-deficiency anemia

Reduces:

- Sickle cell crises among women with sickle cell anemia
- Symptoms of endometriosis (pelvic pain, irregular bleeding)

#### NET-EN

Helps protect against:

None

Known Health Risks

None

Iron-deficiency anemia

NET-EN may offer many of the same health benefits as DMPA, but this list of benefits includes only those for which there is available research evidence.

#### Correcting Misunderstandings (see also Questions and Answers, p. 78)

Progestin-only injectables:

- Can stop monthly bleeding, but this is not harmful. It is similar to not having monthly bleeding during pregnancy. Blood is not building up inside the woman.
- Do not disrupt an existing pregnancy.
- Do not make women infertile.

#### **New Formulation of DMPA**

A formulation of DMPA has been developed specifically for injection into the tissue just under the skin (subcutaneously). This new formulation *must* be delivered by subcutaneous injection. It will not be completely effective if injected in other ways. (Likewise, DMPA for injection into the muscle must not be injected subcutaneously.)


The hormonal dose of the new subcutaneous formulation (DMPA-SC) is 30% less than for DMPA formulated for injection into the muscle— 104 mg instead of 150 mg. Thus, it may cause fewer side effects, such as weight gain. Contraceptive effectiveness is similar. Like users of intramuscular DMPA, users of DMPA-SC have an injection every 3 months.

DMPA-SC will be available in prefilled syringes, including the single-use Uniject system. These prefilled syringes will have special short needles meant for subcutaneous injection. With these syringes, women could inject DMPA themselves. DMPA-SC was approved by the United States Food and Drug Administration in December 2004 under the name "depo-subQ provera 104." It has since also been approved in the United Kingdom.



62 Family Planning: A Global Handbook for Providers

#### Progestin-Only Injectables 63







#### New Problems That May Require Switching Methods

May or may not be due to the method.

#### Migraine headaches (see Identifying Migraine Headaches and Auras, p. 368)

- If she has migraine headaches without aura, she can continue to use the method if she wishes.
- If she has migraine aura, do not give the injection. Help her choose a method without hormones.

Unexplained vaginal bleeding (that suggests a medical condition not related to the method) Progestin-Only Injectabl

- Refer or evaluate by history and pelvic examination. Diagnose and treat as appropriate.
- If no cause of bleeding can be found, consider stopping progestin-only injectables to make diagnosis easier. Provide another method of her choice to use until the condition is evaluated and treated (not implants or a copper-bearing or hormonal IUD).
- If bleeding is caused by sexually transmitted infection or pelvic inflammatory disease, she can continue using progestin-only injectables during treatment.

Certain serious health conditions (suspected blocked or narrowed arteries, liver disease, severe high blood pressure, blood clots in deep veins of legs or lungs, stroke, breast cancer, or damage to arteries, vision, kidneys, or nervous system caused by diabetes). See Signs and Symptoms of Serious Health Conditions, p. 320.

- Do not give next injection.
- Give her a backup method to use until the condition is evaluated.
- Refer for diagnosis and care if not already under care.

#### Suspected pregnancy

- Assess for pregnancy.
- Stop injections if pregnancy is confirmed.
- There are no known risks to a fetus conceived while a woman is using injectables (see Question 11, p. 80).

## Questions and Answers About Progestin-Only Injectables

#### Can women who could get sexually transmitted infections (STIs) use progestin-only injectables?

Yes. Women at risk for STIs can use progestin-only injectables. The few studies available have found that women using DMPA were more likely to acquire chlamydia than women not using hormonal contraception. The reason for this difference is not known. There are few studies available on use of NET-EN and STIs. Like anyone else at risk for STIs, a user of progestin-only injectables who may be at risk for STIs should be advised to use condoms correctly every time she has sex. Consistent and correct condom use will reduce her risk of becoming infected if she is exposed to an STI.

#### If a woman does not have monthly bleeding while using progestin-only injectables, does this mean that she is pregnant?

Probably not, especially if she is breastfeeding. Eventually most women using progestin-only injectables will not have monthly bleeding. If she has been getting her injections on time, she is probably not pregnant and can keep using injectables. If she is still worried after being reassured, she can be offered a pregnancy test, if available, or referred for one. If not having monthly bleeding bothers her, switching to another method may help.

#### Can a woman who is breastfeeding safely use progestin-only injectables?

Yes. This is a good choice for a breastfeeding mother who wants a hormonal method. Progestin-only injectables are safe for both the mother and the baby starting as early as 6 weeks after childbirth. They do not affect milk production.

## 4. How much weight do women gain when they use progestin-only injectables?


Women gain an average of 1-2 kg per year when using DMPA. Some of the weight increase may be the usual weight gain as people age. Some women, particularly overweight adolescents, have gained much more than 1-2 kg per year. At the same time, some users of progestin-only injectables lose weight or have no significant change in weight. Asian women in particular do not tend to gain weight when using DMPA.

#### 5. Do DMPA and NET-EN cause abortion?

No. Research on progestin-only injectables finds that they do not disrupt an existing pregnancy. They should not be used to try to cause an abortion. They will not do so.

#### 78 Family Planning: A Global Handbook for Providers







# For more information

Contact: reproductivehealth@who.int



